Analysis of the inh-2 mechanism of actionconfirmed that it decreases ubiquitination and increases half-lifeof F508del-CFTR, further validating RNF5 as a drug target for CF andproviding evidence to support its druggability.40 This evidence concerns the gene RNF5 and cystic fibrosis.